We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Nebulized Bronchodilators on Heart Rate

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01151579
First Posted: June 28, 2010
Last Update Posted: October 23, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Genesys Regional Medical Center
Information provided by (Responsible Party):
Fahim Khorfan, MD, Genesys Regional Medical Center
  Purpose
The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.

Condition Intervention Phase
COPD Sepsis Shock Drug: Levalbuterol Drug: Albuterol Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Supportive Care
Official Title: Prospective Trial of Effect of Nebulized Bronchodilators on Heart Rate and Arrhythmias in Critically Ill Adult Patients

Resource links provided by NLM:


Further study details as provided by Fahim Khorfan, MD, Genesys Regional Medical Center:

Primary Outcome Measures:
  • Heart Rate in Beats Per Minute [ Time Frame: Five days ]
    Average difference in Heart rate between pre and post breathing treatments


Secondary Outcome Measures:
  • Arrhythmias [ Time Frame: 15 minutes after each treatment for average of 3 to 5 days ]
    Any new arrhythmia documented in the medical record that occurred between breathing treatments.

  • Total Number of Participants With Arrhythmias [ Time Frame: Five days ]
    Documented new arrhythmia occurring during study.


Enrollment: 89
Study Start Date: December 2008
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Levalbuterol 0.63
Patients received an initial dose of levalbuterol 0.63 mg alternating with albuterol 2.5 mg.
Drug: Levalbuterol
inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
Other Names:
  • Xopenex
  • ipratropium
Drug: Albuterol
Nebulized albuterol 2.5mg
Other Name: Salbutamol
Active Comparator: Levalbuterol 1.25
Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.
Drug: Levalbuterol
inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
Other Names:
  • Xopenex
  • ipratropium
Drug: Albuterol
Nebulized albuterol 2.5mg
Other Name: Salbutamol

Detailed Description:
A randomized, single-blind, cross-over, prospective study was conducted in seventy critically ill adult patients with acute air flow obstruction. Patients were randomized to nebulized albuterol alternating with levalbuterol every 4 to 6 hours. Group A received albuterol 2.5 mg alternating with levalbuterol 0.63 mg. Group B received albuterol 2.5 mg alternating with levalbuterol 1.25 mg. All patients received nebulized ipratropium bromide 500 micrograms with each treatment. Heart rate and cardiac rhythm were continuously recorded before and 15 minutes after finishing each treatment. Any new rhythm abnormalities between treatments were also recorded.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults who required inhaled bronchodilator therapy in the form of short acting beta adrenergic receptor agonist and short acting anti-cholinergic treatment every 4-6 hours for respiratory functions

Exclusion Criteria:

  • Known allergy or sensitivity to study medications
  • Baseline heart rate was greater than 110 beats per minute
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01151579


Locations
United States, Michigan
Genesys Regional Medical Center
Grand Blanc, Michigan, United States, 48439
Sponsors and Collaborators
Fahim Khorfan, MD
Genesys Regional Medical Center
Investigators
Principal Investigator: Fahim Khorfan, MD Genesys Regional Medical Center
Study Director: Kimberly R Barber, PhD Genesys Regional Medical Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Fahim Khorfan, MD, ICU Pulmonologist, Genesys Regional Medical Center
ClinicalTrials.gov Identifier: NCT01151579     History of Changes
Other Study ID Numbers: ME 07-0011
First Submitted: June 24, 2010
First Posted: June 28, 2010
Results First Submitted: March 12, 2015
Results First Posted: October 23, 2015
Last Update Posted: October 23, 2015
Last Verified: September 2015

Keywords provided by Fahim Khorfan, MD, Genesys Regional Medical Center:
Tachycardia
tachyarrhythmias
bronchodilator therapy
Critically ill patients

Additional relevant MeSH terms:
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action